Device Trial Radar · NCT07950111
HA380 Hemoadsorption Combined With Continuous Renal Replacement Therapy Versus Continuous Renal Replacement Therapy Alone in Septic Shock
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
70
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Oct 2028
Study completion Nov 2028
Sponsor
- Lead sponsor
- The 108 Military Central HospitalGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- Collaborators
- Vietnam Military Medical University; Thanh Phuong Co., Ltd
- First posted
- Nov 20, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn whether adding an HA380 hemoadsorption cartridge to continuous renal replacement therapy (CRRT) helps adults with septic shock and acute kidney injury requiring CRRT recover from shock better than CRRT alone. Septic shock is a life-threatening condition in which an infection triggers an excessive inflammatory response, causing very low blood pressure and organ failure. The HA380 cartridge is a device placed in the CRRT blood circuit that is designed to remove inflammatory molecules (cytokines) from the blood. The main question it aims to answer is: Does CRRT combined with the HA380 cartridge result in a lower blood lactate level (a marker of poor oxygen delivery to the body's tissues) at 24 hours than CRRT alone? Researchers will also compare the two groups in terms of the amount of blood-pressure-supporting medicines needed, blood levels of inflammatory cytokines, organ function, time to recovery from shock, need for organ support, length of intensive care unit (ICU) and hospital stay, survival up to 28 days, and side effects. Participants will: * Be randomly assigned to receive either CRRT combined with the HA380 cartridge or CRRT alone, in addition to the same standard septic shock care * If assigned to the HA380 group, receive three HA380 cartridges consecutively, each for 6 hours (18 hours in total), followed by CRRT alone as needed * Have their vital signs, medicine doses and blood tests recorded before treatment and at set times up to day 7 * Be followed up for survival and recovery until day 28
Conditions
- Septic Shock
- Acute Kidney Injury
Interventions
HA380 Hemoadsorption CartridgeDevice
Single-use neutral macroporous resin hemoadsorption cartridge (Jafron Biomedical), primed with heparinized saline according to the manufacturer's instructions and connected in series after the M100 hemofilter, before blood returns to the patient. Three cartridges are used consecutively, each for 6 hours (total 18 hours), starting with the first CRRT session
Continuous Renal Replacement TherapyProcedure
Continuous venovenous hemodiafiltration (CVVHDF) on the Prismaflex system with an M100 hemofilter (maximum 24 hours per filter), blood flow 150-200 mL/min, effluent dose 25-30 mL/kg/h, lactate-free bicarbonate-buffered solutions, unfractionated heparin anticoagulation per protocol (no anticoagulation if platelet count \<50 ×10⁹/L); started within 2 hours of randomization.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Arterial Blood Lactate Concentration at 24 HoursTime frame: Baseline and 24 hours after initiation of CRRT
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The 108 Military Central Hospital
Hanoi, Vietnam
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.